We found that ABL1 inhibitors, such as imatinib and dasatinib, exhibited a negative correlation with platinum resistance, suggesting they could serve as potential treatment options for ovarian cancer cells with overexpressed SYCP2 (Fig. 1D). This evidence concerns the gene ABL1 and ovarian carcinoma.